HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HSIC
Henry Schein, Inc.
HSIC's fundamentals are mixed: free cash flow grew 39%, while its operating margin held steady at 5.2%. At 24x earnings, it's trading in line with its usual 22x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HSIC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
HSIC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HSIC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $86.14 | — |
| Cheap | 17x | $60.99 | -29% |
| Fair | 21x | $78.46 | -8.9% |
| Current | 24x | $86.14 | — |
| Expensive | 25x | $90.36 | +4.9% |
Historical ranges are pointers, not guarantees.
HSIC's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HSIC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
HSIC has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HSIC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.82 | +59% |
| Q3 2026 | $3.65 | +15% |
| Q2 2026 | $3.43 | +10% |
| Q1 2026 | $3.31 | +3.1% |
| Q4 2025 | $3.27 | +7.2% |
| Q3 2025 | $3.17 | +30% |
| Q2 2025 | $3.11 | +15% |
| Q1 2025 | $3.21 | +8.1% |
| Q4 2024 | $3.05 | -3.5% |
HSIC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HSIC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HSIC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.5B | +4% |
| Q2 2026 | $3.5B | +6.7% |
| Q1 2026 | $3.4B | +6.3% |
| Q4 2025 | $3.4B | +7.7% |
| Q3 2025 | $3.3B | +5.2% |
| Q2 2025 | $3.2B | +3.3% |
| Q1 2025 | $3.2B | -0.1% |
| Q4 2024 | $3.2B | +5.8% |
HSIC's revenue has grown year over year for six quarters in a row: $3.5B last quarter, up 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.6% | +0.6 points |
| Q2 2026 | 5% | +0.3 points |
| Q1 2026 | 5.4% | -0.1 points |
| Q4 2025 | 4.7% | -0.1 points |
| Q3 2025 | 4.9% | 0 points |
| Q2 2025 | 4.7% | -0.4 points |
| Q1 2025 | 5.5% | +0.8 points |
| Q4 2024 | 4.9% | +3.6 points |
HSIC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HSIC on cash flow, with more consistent year-over-year improvement.
HSIC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $131M | -7.1% |
| Q2 2026 | $212M | +141% |
| Q1 2026 | -$122M | -2133% |
| Q4 2025 | $338M | +101% |
| Q3 2025 | $141M | +21% |
| Q2 2025 | $88M | -66% |
| Q1 2025 | $6M | -96% |
| Q4 2024 | $168M | +$239M |
HSIC generated $559M in free cash flow over the past year, up 39% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HSIC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -1.9M shares |
| 1 year | -7% | -8.5M shares |
| 3 years | -14% | -18.9M shares |
| 5 years | -20% | -28.5M shares |
| Available history | -25% | -36.7M shares |
HSIC has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $125M |
| Q2 2026 | $200M |
| Q1 2026 | $125M |
| Q4 2025 | $200M |
| Q3 2025 | $203M |
| Q2 2025 | $286M |
| Q1 2025 | $161M |
| Q4 2024 | $75M |
HSIC spent $650M buying back its own shares over the past year, down 10% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HSIC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.1x | Elevated |
| Q3 2025 | 3.2x | Elevated |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 2.7x | Moderate |
HSIC's net debt is about 3.2 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HSIC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.0 | Neutral |
| Stochastic | 50.0 | Neutral |
HSIC's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HSIC PE vs Healthcare Sector
| Metric | HSIC | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 8.7% below |
| PE % | 73 | 29 | 44 pts above |
HSIC is trading at 24x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HSIC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.5 | 0.8% above |
| 20 week MA | $86.6 | 0.6% below |
| 50 week MA | $80.8 | 6.7% above |
| 100 week MA | $75.4 | 14% above |
| 200 week MA | $74.8 | 15% above |
HSIC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HSIC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.6 | $65.8 | -1.1% |
| 2021 | $65.8 | $74.9 | +14% |
| 2022 | $74.9 | $80.6 | +7.6% |
| 2023 | $80.6 | $75.7 | -6.1% |
| 2024 | $75.7 | $70.4 | -7% |
| 2025 | $70.4 | $76.1 | +8.1% |
| 2026 YTD | $76.1 | $86.1 | +13% |
HSIC has the edge over HIMS on returns for 2026, with the stronger performance.